osudhkosh
New

৳ 70/unit

Pack: ৳ 700

TabletStrip (10 Tablet)
Save to my medicines
Alert me on price drop

At a glance

Vericiguat is indicated to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

Indications
  • Symptomatic chronic heart failure (ejection fraction <45%)
Pharmacology

Vericiguat is a stimulator of soluble guanylate cyclase (sGC). When NO binds to sGC, the enzyme catalyzes the synthesis of intracellular cGMP, a second messenger that plays a role in the regulation of vascular tone, cardiac contractility, and cardiac remodeling. Heart failure is associated with impaired synthesis of NO and decreased activity of sGC.

Dosage

Adult Dose (Oral):

  • Starting dose: 2.5 mg once daily with food
  • Double the dose approximately every 2 weeks to reach target maintenance dose of 10 mg once daily, as tolerated
Side effects

Common Side Effects:

  • Low blood pressure
  • Low red blood cells (Anemia)
Use in pregnancy

Use in Pregnancy: Contraindicated; may cause fetal harm; exclude pregnancy and use effective contraception.

Pregnancy Category: C — always consult a doctor before taking during pregnancy.

Precautions & warnings
  • May cause fetal harm; exclude pregnancy and use effective contraception
  • Concomitant use with PDE-5 inhibitors not recommended (potential for hypotension)
  • Contraindicated with other sGC stimulators
Overdose effects

Symptoms: Hypotension.

Treatment: Symptomatic treatment; unlikely to be removed by hemodialysis (high protein binding).

Storage conditions

Keep below 30°C, away from light and moisture; keep out of reach of children.

Vericiguat — see the full informationPharmacology, precautions, pregnancy, overdose and the rest on the generic page
⚠️ This information is for educational purposes only — not a substitute for medical advice. Consult a registered physician before taking any medicine.